Exelixis
EXEL
$21.12
Share price
0.62%
Change (1 day)
8.31%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Earnings for Exelixis (EXEL)
Earnings in 2023 (TTM): $0.25 B
According to Exelixis's latest financial reports the company's current earnings (TTM) are $0.25 B. In 2022 the company made an earning of $0.23 B a decrease over its 2021 earnings that were of $0.29 B.The earnings displayed on this page is the company's Pretax Income.
Earnings history for Exelixis from 2001 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2023 (TTM)  | $0.25 B | 9.89% |
| 2022 | $0.23 B | -20.33% |
| 2021 | $0.29 B | 124.82% |
| 2020 | $0.13 B | -67.14% |
| 2019 | $0.39 B | -11.94% |
| 2018 | $0.45 B | 185.09% |
| 2017 | $0.15 B | -325.82% |
| 2016 | -$70.23 M | -58.12% |
| 2015 | -$0.17 B | -37.61% |
| 2014 | -$0.27 B | 9.75% |
| 2013 | -$0.25 B | 65.96% |
| 2012 | -$0.15 B | -291.63% |
| 2011 | $76.99 M | -195.59% |
| 2010 | -$80.55 M | -42.17% |
| 2009 | -$0.14 B | -18.98% |
| 2008 | -$0.18 B | -6.99% |
| 2007 | -$0.19 B | 46.3% |
| 2006 | -$0.13 B | 33.25% |
| 2005 | -$94.81 M | -30.92% |
| 2004 | -$0.14 B | 44.29% |
| 2003 | -$95.12 M | 12.86% |
| 2002 | -$84.29 M | 22.79% |
| 2001 | -$68.65 M |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $21.36 B | 8,163.90% | 🇺🇸 USA |
 Pfizer PFE | $3.26 B | 1,163.78% | 🇺🇸 USA |
 Amgen AMGN | $7.85 B | 2,938.57% | 🇺🇸 USA |
 Sanofi SNY | $7.26 B | 2,708.71% | 🇫🇷 France |
 Merck MRK | $3.03 B | 1,074.04% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | -$5.85 B | -2,361.42% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $6.88 B | 2,563.39% | 🇬🇧 UK |
 Curis CRIS | -$43.93 M | -116.99% | 🇺🇸 USA |
 AVEO Oncology
AVEO | -$29.04 M | -111.23% | 🇺🇸 USA |